ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 891,68
-0,19%
Dow Jones
44 863,75
0,69%
DAX
21 585,93
0,35%
Brent Oil
74,645
-1,71%
Bitcoin
97 708,00
-0,16%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. CG Oncology Inc (CGON)

  7. CG Oncology Inc (CGON) Actualités

CGON

CG Oncology (CGON)

CG Oncology Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CGON
DateHeureSourceTitreSymboleSociété
10/01/202522h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGONCG Oncology Inc
18/12/202400h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGONCG Oncology Inc
16/12/202422h05GlobeNewswire Inc.CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CGONCG Oncology Inc
13/12/202422h07Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CGONCG Oncology Inc
13/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGONCG Oncology Inc
13/12/202402h19GlobeNewswire Inc.CG Oncology Announces Pricing of Public OfferingNASDAQ:CGONCG Oncology Inc
11/12/202422h09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:CGONCG Oncology Inc
11/12/202412h17GlobeNewswire Inc.CG Oncology Announces Proposed Public OfferingNASDAQ:CGONCG Oncology Inc
06/12/202414h00GlobeNewswire Inc.SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardNASDAQ:CGONCG Oncology Inc
05/12/202413h00GlobeNewswire Inc.Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
02/12/202414h00GlobeNewswire Inc.CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024NASDAQ:CGONCG Oncology Inc
20/11/202414h00GlobeNewswire Inc.CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual MeetingNASDAQ:CGONCG Oncology Inc
12/11/202414h00GlobeNewswire Inc.CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
11/11/202414h00GlobeNewswire Inc.CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGONCG Oncology Inc
30/08/202414h00GlobeNewswire Inc.CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:CGONCG Oncology Inc
30/08/202402h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGONCG Oncology Inc
08/08/202414h23GlobeNewswire Inc.CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
08/08/202412h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGONCG Oncology Inc
18/06/202414h00GlobeNewswire Inc.CG Oncology Initiates Expanded Access Program for Cretostimogene GrenadenorepvecNASDAQ:CGONCG Oncology Inc
06/06/202418h14GlobeNewswire Inc.CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBCNASDAQ:CGONCG Oncology Inc
24/05/202414h00GlobeNewswire Inc.CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
09/05/202414h00GlobeNewswire Inc.CG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
03/05/202417h23GlobeNewswire Inc.Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
26/04/202414h00GlobeNewswire Inc.CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024NASDAQ:CGONCG Oncology Inc
24/04/202416h00GlobeNewswire Inc.CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024NASDAQ:CGONCG Oncology Inc
28/03/202413h00GlobeNewswire Inc.CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
27/02/202414h00GlobeNewswire Inc.CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
30/01/202413h00Business WireCG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CGONCG Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:CGON

Dernières Valeurs Consultées

NYSE
NKE
Nike
NYSE
MRK
Merck
EU
ML
Michelin
EU
PX4
SBF 120
EU
VIV
Vivendi
EU
BEL20
Bel 20
EU
GLE
Societe Generale
NYSE
DIS
Walt Disney
EU
VK
Vallourec
COIN
AVAXUSD
Avalanche
EU
BNP
BNP Paribas
EU
EN
Bouygues
EU
ORA
Orange
COIN
ADAUSD
Cardano
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces